Investment Case
hVIVO is a purpose-built, full-service, expert-led international clinical development partner and the global leader in human challenge trials.
Fully integrated, end-to-end platform spanning preclinical strategy to clinical proof-of-concept.
hVIVO owns state-of-the-art, purpose-built facilities including world-class CL3 labs and quarantine units in London and clinical research sites across the UK and Germany.
hVIVO’s FluCamp platform is the largest specialist participant recruitment database in the UK and Europe combined, with over 400,000 volunteers and 100% recruitment success rate.
The Company is debt free and has Cash of c.£14.3 million as at 31 December 2025.
Well-funded to execute on its strategy to scale the business and deliver sustainable growth.
hVIVO’s end-to-end platform, which spans preclinical strategy through to clinical proof-of-concept, will ensure consistent sustainable long-term growth.
The Group has a strong sales pipeline across its four integrated, synergistic service lines, which have been built to drive cross-selling and operational leverage.
Three key targeted growth initiatives across cardiometabolic, respiratory and laboratory services.
Scalable model leveraging existing infrastructure, with limited capital requirements.
The global biopharma industry is facing increasing pressure to generate high-quality validating proof-of-concept clinical evidence faster.
Greater complexity in early-stage development is driving outsourcing to specialist partners.
Over $300bn in upcoming patent expiries is driving R&D investment and deal activity.
hVIVO offers a unique combination of international scale, proprietary infrastructure and owned clinical research sites all under one roof, that other mid-sized CRO competitors cannot replicate.
The global leader in human challenge trials with heritage dating back to the 1940s, hVIVO has unmatched operational experience and in-house expertise.
hVIVO works with seven of the 10 largest global biopharma companies.
Its trials are designed, executed and interpreted by recognised domain experts and key opinion leaders.
Holds a strong track record supporting Fast Track and Breakthrough designations and high-value M&A outcomes.
Looking for our latest results?
Visit our Results Centre
